Health Canada Approves Butterfly iQ+ Platform

Butterfly Network Inc. (Butterfly) announced that its second-generation iQ+ has been approved for a Class III Medical Device License in Canada. The iQ+ features the world’s only Ultrasound-on-Chip technology, with several hardware and software advances designed to improve usability and care delivery.
 
“We are excited that the Butterfly iQ+ will now be available for purchase by Canadian medical professionals,” said Todd Fruchterman, M.D., Ph.D., president and CEO of Butterfly Network. “Thousands of new practitioners and millions of patients will now have access to a transformative advanced assessment tool that can deliver valuable insights that enable more informed clinical decisions at the point of care.”
 
Innovative Technology
Butterfly iQ+ will help unlock the power of medical imaging earlier in the treatment journey with an entire suite of advanced imaging features, such as real-time Biplane Imaging (the first such feature for a handheld ultrasound device), automatic bladder volume calculation with 3D rendering, Needle Viz onscreen needle highlighting, and Pulsed Wave Doppler. It includes Educational View Guidance, which helps clinicians improve their scanning technique by providing a visual indication of the quality of the image being collected. Relative to the first-generation device, the iQ+ is built to perform even more reliably throughout demanding shifts with 20 percent extended battery life and 15 percent faster frame rates, and has a smaller form factor that allows for tighter control.
 
Butterfly iQ+ can be coupled with its integrated enterprise software solution that allows clinicians to scan, document, upload, and review images seamlessly. More integrated workflows and educational resources, including tutorial videos and remote scanning assistance via TeleGuidance, will allow Canadian healthcare providers to quickly implement Butterfly iQ+ into their practices.
 
The Butterfly iQ+ is well suited for the needs of the Canadian healthcare system, consisting of over 86,000 physicians¹ across 830 hospitals.² Demand for Butterfly’s first-generation iQ device, launched in Canada in March 2020, has been very strong. Butterfly iQ+’s advanced features, improved usability, and functionality are expected to further accelerate demand and deliver more value.
 
With Canada’s approval, Butterfly iQ+ is now available in 20 countries across the world.
 
Founded by Dr. Jonathan Rothberg in 2011 and recently listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly Network created the world’s only handheld, single-probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ. Its mission is to democratize medical imaging and contribute to the aspiration of global health equity by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected—including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. 

References
¹ Canadian Medical Association
² Definitive Healthcare